Tamoxifen
rechallenge in patients with prior adjuvant tamoxifen
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
Someone who’s been on tamoxifen for three years, had kind of
borderline steroid receptors, and who progresses, it may be a patient
who is quite different than a patient who got five years of tamoxifen,
quit seven years ago, and now has shown up with a couple of gradually
growing chest wall metastasis. Certainly in the later case one would
feel very comfortable putting the patient back on tamoxifen and
the former case one would be very uncomfortable rechallenging the
patient a couple of years later. And again, I think this is going
to come down very much to the physician’s gestalt about the
situation one’s in. But, it seems that in one case you’re
dealing with true tamoxifen resistance, in the another case you
may well be dealing with inadequate duration of therapy.
Tamoxifen
adjuvant treatment duration in early breast cancer: Initial results
of a randomized study comparing short-term treatment with long-term
treatment. Delozier,
T.; Spielmann, M.; Mace-Lesec'h, J.; Janvier, M.; Hill, C.; Asselain,
B.; Julien, J. P.; Weber, B.; Mauriac, L.; Petit, J. C.; Kerbrat,
P.; Malhaire, J. P.; Vennin, P.; Leduc, B., and Namer, M.. Journal
of Clinical Oncology. 18(20):3507-3512, 2000 Oct 15.
